电话:
+86 (0512) 65829739
传真:
+86 (010) 6788 5057
电子邮件:
orders@antibodies-online.cn

Clvs1/2 抗体 (C-Term)

This anti-Clvs1/2 antibody is a 兔 多克隆 antibody detecting Clvs1/2 in IF 和 WB. Suitable for 人, 小鼠 和 大鼠.
产品编号 ABIN784598
发货至: 中国

Quick Overview for Clvs1/2 抗体 (C-Term) (ABIN784598)

抗原

Clvs1/2 (Clavesin 1/2 (Clvs1/2))

适用

人, 小鼠, 大鼠

宿主

克隆类型

多克隆

应用范围

Immunofluorescence (IF), Western Blotting (WB)
  • 抗原表位

    C-Term

    特异性

    Specific for the ~35 kDa Clavesin 1/2 protein doublet in Western blots of Rat brain lysate. Isoform-specific knock down in cultured hippocampal neurons indicates that the lower and upper bands are Clavesin 1 and 2, respectively.

    交叉反应 (详细)

    Species reactivity (expected):Human and Mouse.
    Species reactivity (tested):Rat.

    纯化方法

    Affinity Chromatography.

    免疫原

    Synthetic peptide KLH-conjugated corresponding to amino acid residues from the C-terminal region of Rat Clavesin-1. Genename: CLVS1/2

    亚型

    IgG
  • 应用备注

    Optimal working dilution should be determined by the investigator.

    限制

    仅限研究用
  • 状态

    Liquid

    缓冲液

    PBS containing 50 % Glycerol.

    注意事项

    Avoid repeated freezing and thawing.

    储存条件

    -20 °C

    储存方法

    Store the antibody undiluted (in aliquots) at -20 °C.
  • 抗原

    Clvs1/2 (Clavesin 1/2 (Clvs1/2))

    背景

    Clavesin (clathrin vesicle associated Sec14 protein) is a novel neuron specific protein that has recently been identified and shown to be required for normal morphology of late endosomes and/or lysosomes as lentiviral-mediated knockdown of clavesin in hippocampal neurons causes lysosomal defects (Katoh et al., 2009). Additionally, upregulation of clavesin in human hepatocellular carcinoma has recently been demonstrated thus making it a useful marker for this disease state (Zhao et al., 2008).Synonyms: C6orf212, C6orf213, CLVS1, CLVS2, CRALBPL, Cellular retinaldehyde-binding protein-like, RLBP1L1, RLBP1L2, Retinaldehyde-binding protein 1-like 1/2

    基因ID

    366311

    NCBI登录号

    NP_001102439
You are here:
Chat with us!